Summary
A medRxiv preprint reports that RNF213 activity is regulated by a switch between closed and open protein dimers. The authors say Moyamoya-associated mutations can destabilise the closed state and bypass this control in laboratory experiments.
A medRxiv preprint posted on 11 October 2026 describes a structural switch that regulates the activity of RNF213, a protein involved in innate immune signalling. The authors report that Moyamoya-associated mutations can destabilise the protein’s normally restrained state, bypassing part of that control in structural, biochemical and cellular experiments.
The findings offer a proposed molecular explanation for how changes in RNF213 may contribute to Moyamoya angiopathy. They are mechanistic research, not evidence from a treatment trial, and the preprint has not yet been peer reviewed.
How the RNF213 switch works
RNF213 is a large protein with both AAA+ and ubiquitin-ligase functions. The preprint describes RNF213 molecules assembling as a dimer that can occupy two states. In the closed state, contacts between the two molecules conceal the protein’s ubiquitin-ligase machinery. When ATP binds, changes in the AAA+ region help open the dimer and prepare RNF213 to carry out ubiquitination—the attachment of ubiquitin molecules to proteins.
According to the authors, this closed-to-open transition can be adjusted by ubiquitination factors, redox conditions and post-translational modifications. These mechanisms could allow different stress signals to influence RNF213 activity through a shared structural switch, rather than each signal requiring a separate activation route.
What the Moyamoya mutations change
The researchers report that Moyamoya-associated mutations disrupt contacts at the dimer interface and make the closed, inhibited state less stable. The degree of destabilisation varied with the mutations and, the authors say, tracked with clinical severity. In their experiments, the altered proteins could bypass ATP-dependent control and drive NF-κB inflammatory signalling and caspase-dependent apoptosis, a form of programmed cell death.
This provides a possible link between inherited susceptibility and cellular responses relevant to disease. Moyamoya angiopathy affects blood vessels supplying the brain; the proposed mechanism may help explain how RNF213 variants contribute to disease risk, while leaving room for other influences on whether disease develops and how severe it becomes.
The study is presented as structural, biochemical and cellular evidence. Its abstract does not specify the experimental models, sample sizes or clinical severity measurements, so the findings are best read as a proposed molecular mechanism rather than a measure of risk or a basis for clinical decisions.